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Abstract 30 
 31 
Objectives: Warfarin is commonly initiated post-cardiac surgery to reduce the risk of 32 
intra-cardiac thrombus formation.  Studies have found that sensitivity is increased 33 
after cardiac surgery and anti-coagulation is subsequently difficult to manage.  This 34 
study set out to identify clinical markers of increased warfarin sensitivity in 35 
patients’ post-cardiac surgery, and build a model that can predict warfarin 36 
sensitivity, and improve safety in this setting. Methods: The study was an 37 
observational, retrospective cohort design.  Clinical parameters including Left 38 
Ventricular Ejection Fraction (LVEF), cross-clamp time, age, serum albumin and C-39 
reactive protein concentrations were collected from consenting patients who had 40 
undergone cardiac surgery and prescribed post-operative warfarin. Warfarin Dose Index 41 
(WDI) was calculated for each patient from their INR and warfarin dose, as a measure 42 
of sensitivity. Results: 41 patients were recruited to the study.  Logarithmically 43 
transformed WDI (log WDI) significantly correlated with LVEF, cardiopulmonary bypass 44 
(CPB) time, cross-clamp time, baseline INR and co-administration of amiodarone 45 
(p<0.05).  When added to a linear regression model, LVEF and cross-clamp time produced 46 
a model that accounted for 41% of variance in log WDI (R2=0.41), p=0.0002).  Applying 47 
a log WDI cut-off value of -0.349 discriminated between patients who develop an INR 48 
>4 and those who do not with a sensitivity of 75% and a specificity of 70%.  49 
Conclusions: This single centre study has highlighted two risk factors for increased 50 
warfarin sensitivity post-cardiac surgery.  Further research is needed to confirm 51 
these findings in a wider, more diverse population, and to validate this model.  52 
 53 
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1. Introduction 59 
Warfarin is an anticoagulant medication used for the treatment and prevention of 60 
thromboembolic disorders such as deep vein thrombosis and pulmonary embolism [1].  It 61 
inhibits the enzyme Vitamin K Epoxide Reductase (VKOR), blocking the formation of 62 
reduced vitamin K, which is necessary for the synthesis of the clotting factors II, 63 
VII, IX, X, and of the anticoagulants protein C and protein S [2].  There is wide 64 
inter-patient variability in the response to warfarin, and as a consequence dosing 65 
needs to be tailored to individual patients.  Factors that are known to affect warfarin 66 
response include diet, co-administration of interacting drugs and single nucleotide 67 
polymorphisms for the genes that code Cytochrome P450 isoenzyme CYP2C9 and VKOR [1].   68 
 69 
Another factor which is increasingly recognised as affecting the sensitivity to 70 
warfarin is a recent history of cardiac valve surgery.  Studies have found that in 71 
the initial post-operative period following valve replacement, certain patients show 72 
an exaggerated response to warfarin when compared to non-surgical patients [3-5].  73 
The sensitivity appears to be prolonged, and can lead to poor control in the 3-month 74 
period after valve replacement [6].  However, after this period, sensitivity is 75 
thought to return to normal.  There is therefore a critical window for potential harm, 76 
especially during period of warfarin loading.  There is variation in this population 77 
however, and whilst some patients show increased sensitivity to warfarin, others do 78 
not.  A universal, bespoke dosage regimen in this population may therefore be 79 
inappropriate. 80 
 81 
Theories for the increased sensitivity include myocardial dysfunction and fluid 82 
overload during surgery, which has been hypothesized to lead to hepatic congestion 83 
which then may affect warfarin metabolism or the synthesis of clotting factors [3-84 
7].  As warfarin is 99% bound to plasma proteins (mainly albumin), hypoalbuminemia, 85 
caused by an inflammatory response or haemodilution as a consequence of 86 
cardiopulmonary bypass (CPB), may also be implicated [3-4,8].  Interacting drugs 87 
 4 
commonly used after cardiac surgery are also expected to influence sensitivity [9, 88 
14-15].  In studies looking at factors influencing sensitivity in this patient group, 89 
baseline INR, serum albumin, amiodarone and antimicrobial prophylaxis have been 90 
identified as risk factors [3, 9-11].   91 
 92 
Despite studies finding increased sensitivity in patients after cardiac valve surgery, 93 
and the identification of various factors that may contribute to altered response, 94 
guidance on dosing in this patient group remains limited, and, as a consequence, 95 
anticoagulation is poorly managed.  A recent study by Roberts et al investigated the 96 
implementation of a warfarin dosing protocol post-valve surgery, suggesting a 30% 97 
reduction in warfarin doses in all patients.  However, this strategy, whilst reducing 98 
the risk of bleeding complications, may leave some non-sensitive patients under-99 
anticoagulated, and at risk of thrombus formation [12].  Another study by Meijer et 100 
al developed a specific dosing algorithm post valve-surgery.  Despite improving the 101 
individual time in therapeutic range, patients in the algorithm group spent more time 102 
with a supra-therapeutic INR compared with the non-algorithm group [13].  Identifying 103 
clinical and biochemical markers that are associated with increased postoperative 104 
sensitivity, and then incorporating them into a risk prediction tool could therefore 105 
aid the personalization of dosing in this setting and minimize the risk of over-106 
anticoagulation and the associated risk of bleeding.   107 
 108 
The published evidence of increased sensitivity is currently limited to patients that 109 
have undergone cardiac valve surgery, however, many of the hypotheses to explain the 110 
increased sensitivity are pertinent to patients undergoing other types of cardiac 111 
surgery, for example, coronary artery bypass graft.  Here, damage to the myocardium 112 
as a result of ischaemia during aortic clamp may lead to an acute deterioration in 113 
left ventricular function, and hepatic congestion, and altered sensitivity to 114 
warfarin. The purpose of the current study was therefore to identify clinical and 115 
biochemical markers of increased warfarin sensitivity in patients that have undergone 116 
 5 
a range of cardiac surgeries, and to build a model that could, after validation, be 117 
used to predict the risk of warfarin sensitivity in the immediate post-operative 118 
period.  The model could also be used to provide guidance on warfarin dosing.   119 
 120 
 121 
 122 
 123 
 124 
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2. Methods 127 
The study was a non-interventional, retrospective cohort study.  It received approval 128 
from the National Health Service Research Ethics Service (REC approval number: 129 
15/EE/0082).  Data were collected as a convenience sample, between April 2015 and 130 
September 2015, from consenting patients. 131 
 132 
2.1 Inclusion criteria 133 
1. Inpatient admission following cardiac surgery (not limited to valve 134 
repair/replacement) 135 
2. Prescribed postoperative warfarin 136 
3. Over 18 years  137 
4. Capacity to consent as determined by the patients’ ability to retain and understand 138 
the information given on the patient information sheet 139 
 140 
2.2 Exclusion Criteria 141 
1. Acute or chronic liver failure as determined from the patient’s medical history 142 
and preoperative liver function tests 143 
2. Baseline INR >1.5  144 
 145 
2.3 Data collection 146 
Participants were given a Patient Information Sheet (PIS) prior to surgery and 147 
enrolled in the study towards the end of their inpatient stay after they had recovered.  148 
The following data were then collected for each participant: demographics, type of 149 
surgery, cardio-pulmonary bypass (CPB) time, cross clamp-time, urea and electrolytes 150 
(U&Es), C-reactive protein (CRP), liver function tests (LFTs), International 151 
Normalised Ratio (INR), left ventricular ejection fraction (LVEF), concurrent 152 
medication prescribed, medication history, warfarin dose, indication and target INR.  153 
Warfarin dose index (WDI) was used as an outcome measure for warfarin sensitivity 154 
(Equation 1, [11]).  The WDI is a well-established measure of sensitivity during both 155 
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warfarin initiation, and maintenance stages.  The index normalizes the patient’s 156 
clotting time (international normalized ratio [INR]) at day 4 following commencement 157 
of warfarin loading, to dose mean dose over the preceding 3 days. 158 
 159 
Equation 1: WDI=INR (day 4*)/mean warfarin dose for preceding 3 days 160 
* Post warfarin loading 161 
 162 
2.4 Statistical power calculation 163 
Sample size was calculated using the ‘pwr’ package in R (v3.2.1).  For a final linear 164 
regression model with between 3-5 predictor variables, a sample of 35-42 patients is 165 
required to detect a large effect (F2=0.35) with α=0.05 and β-1=0.80.  For the same 166 
number of predictors (3-5) and an F2=0.15 (medium effect) a sample size of 77-91 167 
patients is required.  We anticipated that our predictors would have a medium to large 168 
effect and so our target sample size was set to 35-50. 169 
 170 
2.5 Statistical model 171 
We built a linear regression model using the log10 of the WDI (log WDI) as our dependent 172 
variable, and factors hypothesized to alter warfarin sensitivity as our predictor 173 
variables.  To determine which of the predictor variables collected should be included 174 
in our first iteration of the model we performed a series of correlations between 175 
these variables and log WDI.  A Pearson Correlation was used for continuous variables 176 
that 1) demonstrate a normal distribution and 2) have no significant outliers [14-177 
15].  For variables with a significant (p<0.05) Shapiro-Wilk test, or where there are 178 
extreme outliers in the sample, a Spearman Rank test was performed [15, 17].  For 179 
dichotomous predictor variables a Point-Biserial Correlation was performed after 180 
assessing normality and homogeneity of variance [14, 17].  Correlation coefficients 181 
are reported as r (Pearson’s), ρ (Spearman’s) and ρpb (Pearson’s Point Biseral).  182 
Variables with a p value of ≤0.15 were then added to a linear regression model with 183 
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log WDI as the dependent variable.  A significance level of p <0.05 was accepted as 184 
statistically significant. 185 
 186 
In describing continuous data with a normal distribution, mean ± standard deviations 187 
were used.  For continuous data that was not normally distributed the median and 188 
interquartile ranges (IQR) is presented.  Our final model was tested for the following 189 
assumptions of linear regression: independence of errors, collinearity, normal 190 
distribution of errors, linearity and heteroscedascity [13-21].  The British Society 191 
of Echocardiography Guidelines were used to categorise LVEF into groups [22].   192 
 193 
Receiver operating characteristics curves, area under the receiver operator curves 194 
(AUROC), and sensitivity and specificity values were calculated using Graphpad Prism 195 
6.0.  Youden’s index was calculated as: (sensitivity + specificity)-1.  The AUROC and 196 
Youden’s index were used to determine an appropriate cut-off value for log WDI to 197 
predict INR >4 during inpatient stay with maximum sensitivity and specificity. 198 
 199 
Data analysis was conducted with SPSS version 22.0, Graphpad Prism 6.0, and R. 200 
 201   202 
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3. Results  203 
 204 
Out of 55 patients admitted for cardiac surgery and initiated on warfarin during the 205 
study period, 41 patients were eligible for inclusion in the study.  35 of these 206 
patients had a complete dataset and were included in the final model (Figure 1).  A 207 
breakdown of baseline demographic details is found in Table 1.  Patients received 208 
post-operative warfarin for a range of indications including atrial fibrillation, 209 
mechanical mitral valve replacement, and mitral valve repair (Table 2). Of the 35 210 
patients included in the final model, 31 were admitted for valve related surgery, and 211 
4 for non-valve related surgery.  Non-valve related surgery included coronary artery 212 
bypass graft (CABG), atrial ablation, and surgical treatment of atrial myoxoma and 213 
left atrial appendage occlusion. 214 
 215 
3.1 Dosing and INR Ranges 216 
Warfarin was started a median of 1 day after surgery (IQR = 1 - 3, range 0 - 18 days) 217 
and took a median of 5 days to reach the therapeutic range (IQR 4 - 7 days, range 3 218 
- 21 days).  Over the first 3 days of loading a median dose of 4 mg daily was used 219 
(IQR 3 – 5 mg).  The median cumulative dose to achieve therapeutic range was 20 mg, 220 
(IQR 13.0 - 27.5 mg). 221 
 222 
Fifteen (37%) patients had an INR value which exceeded the patient’s target 223 
therapeutic range for a median of 2.5 days (IQR 2 – 4.5 days, range 1 - 6 days) and 224 
of these, 12 (80%) patients had an INR > 4.0.  One patient had vitamin K administered 225 
to reverse an INR of 7.5.  During the study 10 (24%) patients had a total of 39 doses 226 
omitted due to the INR exceeding the therapeutic range.  Discharge was delayed in 227 
four patients (10%) due to the INR being below the therapeutic range and one patient 228 
had a delayed discharge due to the INR being too high.  Comparing valve and non-valve 229 
related surgery patients, 9/31 in the valve related surgery group, and 3/4 in the 230 
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non-valve related surgery group developed and INR >4 during loading with warfarin 231 
post-surgery. 232 
 233 
3.2 Bivariate Correlation 234 
To identify variables to enter in the first iteration of our model we performed a 235 
series of statistical correlation tests between log WDI and predictor variables 236 
(supplementary material).  From these correlations we identified left ventricular 237 
ejection fraction (LVEF), CPB, cross-clamp time, baseline INR, and the co-238 
administration of amiodarone and omeprazole as potential predictors.  Other factors 239 
that have previously been associated with warfarin sensitivity, such as age, gender 240 
and weight were not significantly correlated with log WDI in this sample (ρ=0.019, 241 
p=0.907 age; rpb=0.056, p=0.728 gender; r=-0.068, p=0.676 weight) and therefore were 242 
not included in the model.   243 
 244 
3.3 Linear regression 245 
Initially the predictors identified were added to the linear regression model as 246 
single variables.  As single predictors of sensitivity LVEF, cross clamp-time, CPB 247 
time and the addition of amiodarone (n=20/41) all had statistically significant 248 
changes in the F-ratio, F (1,33) = 15.87, p = 0.00035, F (1,39) = 4.817, p = 0.034, 249 
F (1,39) = 4.665, p = 0.037 and F (1,39) = 4.743, p = 0.036 respectively.  As a single 250 
predictor LVEF accounted for 32.5% of variability in the model (R2 = 0.325, adjusted 251 
R2 = 0.304, n=35, Figure 2) and when combined with cross-clamp time the model accounted 252 
for 41% of the variance ((R2 = 0.41, adjusted R2 = 0.373, n=35).  The combination of 253 
LVEF and length of cross-clamp time provided the best fit of the data (Table 3).  The 254 
addition of amiodarone (F change = 1.307, p = 0.261), or CPB time (F change = 2.858, 255 
p = 0.101) to LVEF did not significantly improve the model.  The equation for our 256 
final model is shown in equation 2, in which E[LogWDIi] is the expected values of 257 
LogWDIi. 258 
 259 
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Equation 2: E[LogWDIi] = 0.026 + (-0.011 x LVEFi) + (0.002 x clamptimei). 260 
 261 
3.4 Model Assumptions 262 
Independence of residuals was confirmed with a Durban Watson test = 2.607.  There was 263 
a small correlation between LVEF and cross-clamp time (r = .130) but assessment of 264 
collinearity was acceptable (VIF = 1.017).  There was a normal distribution of the 265 
residuals as confirmed with a frequency histogram and a P-P plot.  From visual 266 
inspection of a plot of standardised predicted values against standardised residuals 267 
there was no evidence of non-linearity or heteroscedascity.  To detect outliers, the 268 
standardised residuals were set at ± 3 (z-score = 2.56), which all were below this 269 
range.   The leverage value calculated was 0.086 and 2 cases had values greater than 270 
twice this value but the Cooks distances conformed to the accepted criteria so none 271 
of the data points would exert a high influence over the regression line. 272 
 273 
3.5 Clinical Predictors 274 
Left Ventricular Ejection Fraction (LVEF): 18 (51%) patients had good LVEF, 12 (34%) 275 
mild LVEF, 2 (6%) moderate LVEF and 3 (9%) poor LVEF. Log WDI was statistically 276 
significantly different amongst the groups (p = 0.033, n=35, Kruskal-Wallis). 277 
 278 
3.6 Using the model to predict patients who develop INR >4 during stay 279 
Using a patient’s LVEF and cross-clamp time to predict log WDI may be of benefit to 280 
clinicians who are initiating warfarin, as it could, for example, be used to calculate 281 
the mean daily loading dose required to reach a target INR by day 4.  This may not 282 
however be practical in a busy ward situation, and may introduce a focal point for 283 
medication error due to the multi-step nature of the calculation required to determine 284 
a loading dose.  It may therefore be more useful to use the model to categorise 285 
patients as either high-risk, or low-risk; those individuals deemed high risk should 286 
then be loaded more cautiously with warfarin.  To use the model in this way, we must 287 
first identify a ‘cut-off’ value in the ‘predicted’ log WDI above which there is high 288 
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sensitivity and specificity for detecting high-risk individuals. High-risk 289 
individuals in this case were considered those patients’ who had developed an INR ≥4 290 
during their inpatient stay.  From our dataset we categorised patients according to 291 
whether they had developed an INR ≥4, and then calculated their ‘predicted’ log WDI 292 
using equation 2.  This allowed us to construct a Receiver Operating Characteristics 293 
(ROC) curve to determine an appropriate cut-off value (Figure 3).  294 
 295 
From our study, 12/35 patients had an INR of ≥4 during their inpatient stay.  We 296 
identified a predicted log WDI cut-off value of -0.380 from our ROC curve (area under 297 
ROC = 0.7 (0.5-0.9), Figure 2).  Using this cut-off value, we correctly identified, 298 
retrospectively, 9/12 patients who went on to develop a peak INR >4 during their 299 
inpatient stay (sensitivity 75%), and 17/23 patients with a peak INR <4 during 300 
inpatient stay (specificity 70%).   Youden’s index, which is a measure of the accuracy 301 
of our model, was calculated as J=0.45, and the positive predictor, and negative 302 
predictor values as 56% and 85% respectively.  303 
 304 
 305   306 
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4 Discussion 307 
 308 
This study aimed to build a model to predict warfarin sensitivity in patients 309 
undergoing cardiothoracic surgery, using a range of routinely available clinical 310 
variables.  In doing so we discovered that compromised cardiac function and the time 311 
spent on clamp increased the risk of developing sensitivity to warfarin post-surgery. 312 
 313 
During the study, 37% of patients exceeded their target INR range.  Of these, 29% had 314 
an INR > 4.0.  For this population, these results are comparable with other studies 315 
looking at warfarin response after cardiac surgery, where between 38% and 48.8% of 316 
patients exceeded the therapeutic range [3, 5] and 25% patients had an INR ≥4.0 in 317 
the induction period [4].  Whilst there is no current guideline for dosing patients 318 
after surgery in the UK, the range of dosing used was consistent for the majority of 319 
patients over the first 3 days of loading, with a median of 4 mg daily (IQR 3 – 5 320 
mg).  Whilst other studies have suggested dosing all patients at lower doses [7], or 321 
applying a dosing algorithm to reduce the risk of high INRs during this period, this 322 
could result in delayed discharges due to sub therapeutic INRs.  Therefore, a targeted, 323 
individualized approach to dosing would be advantageous, in terms of the patient 324 
experience, safety, and healthcare associated costs.   325 
 326 
Of the factors hypothesized to be associated with increasing warfarin sensitivity, 327 
LVEF had a large effect size (r=0.57) and a statistically significant negative 328 
correlation associated with increased response to warfarin.  CPB time, amiodarone and 329 
baseline INR were also found to have statistically significant positive correlations 330 
with the outcome measure, all with medium effect sizes.  However, when added to our 331 
regression model, they did not increase the explanatory power of LVEF in predicting 332 
warfarin sensitivity.  This study was not powered to assess this further. 333 
 334 
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4.1 Heart Failure 335 
The negative relationship between LVEF and warfarin sensitivity is perhaps 336 
counterintuitive: warfarin is a low extraction drug, and elimination is not considered 337 
to be dependent upon hepatic blood flow [23], which is compromised in heart failure 338 
(a low LVEF).  However, there are reports of an association between heart failure and 339 
increased response to warfarin in the literature, although some of these studies are 340 
older and problematic.  For example, some used prothrombin time rather than INR [24] 341 
as a measure of warfarin efficacy, the parameters of which can vary between 342 
laboratories.   343 
 344 
There are also conflicting findings between whether dose requirements are altered 345 
because of decompensated heart failure, or if the effect also manifests for stable 346 
heart failure [24].  A small study (n = 63) looking for factors affecting the 347 
maintenance dose in Hong Kong Chinese patients, found that chronic heart failure (n 348 
= 6) negatively correlated with warfarin dosage requirement (r = - 0.26, p = 0.025) 349 
[25].  Doecke et al. (1991) also found that stable chronic heart failure was associated 350 
with increased response to warfarin during initiation [26].  351 
 352 
Del Campo et al (2015) found warfarin sensitivity (WDI) to be significantly increased 353 
during exacerbations of heart failure and chronic obstructive pulmonary disease (COPD) 354 
when compared to a periods of disease stability [27].  The heart failure group had 355 
significantly greater sensitivity at admission compared to the COPD and control groups 356 
but no difference in sensitivity between the groups during periods of disease 357 
stability.  This would indicate a transient change, relating to the exacerbation, 358 
which supports the theory relating to increased sensitivity for decompensated disease.  359 
Significantly more patients presented with INR ≥ 4 in NYHA class 3 and 4 compared to 360 
NYHA class 1 and 2 (41% vs. 7% respectively p = 0.028), indicating increased 361 
sensitivity with worsening function as found in this study.   362 
 363 
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Theories relating to proposed mechanisms for increased response in heart failure 364 
exacerbations relate to either the pharmacodynamic effect on clotting factor 365 
synthesis, or proposed pharmacokinetic mechanisms of reduced warfarin metabolism or 366 
clearance.  As the liver is the site of synthesis for vitamin K dependent clotting 367 
factors, a decrease in synthesis due to hepatic congestion has been suggested [24].  368 
 369 
4.2 Cardiopulmonary Bypass Time, Cross-clamp Time and Warfarin Sensitivity  370 
Cardiopulmonary bypass is the use of an extracorporeal circuit to maintain circulation 371 
to the body during cardiothoracic surgery [28].  A cross-clamp is placed across the 372 
aorta to isolate the coronary circulation and can, in some circumstances lead to 373 
hypoxic damage of the myocardium, although various techniques are used to mitigate 374 
this [28].   Increasing length of cross-clamp time and CPB time were both found to be 375 
significantly correlated with increasing warfarin sensitivity and may be related to 376 
ensuing damage. However, other studies in this patient group did not find any 377 
relationship between CPB times in either of their cohorts when looking at warfarin 378 
sensitivity [11, 14], but may be related to differences in surgical procedures or 379 
patient demographics.   380 
 381 
Both prolonged CPB and cross-clamp time are associated with increased morbidity and 382 
mortality following cardio-thoracic surgery.  There is evidence that during the period 383 
of the cross-clamp, myocardial ischemia induces a systemic inflammatory response 384 
syndrome (SIRS) [29].  Pro-inflammatory cytokines, including interleukin 6 (IL-6), 385 
tumour necrosis factor α (TNF- α), interleukin 1 (IL-1) and endotoxin are released as 386 
part of the SIRS response, thought to result from the exposure of blood to the 387 
artificial surface of the bypass circuit [29-30].  Cytokines, such as IL-1, IL-6, TNF 388 
α and interferon have all been shown to have an effect on drug metabolism [31].  389 
Production of cytokines, which may be responsible for the down regulation of 390 
individual CYP450 isoforms has been proposed as a mechanism for significant decreases 391 
in CYP450 related drug metabolism in critically ill patients with SIRS [32-33].  Peak 392 
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CRP was investigated in this study as a marker of inflammation but did not 393 
significantly correlate with log WDI, having a small effect size.  As IL-6 seems to 394 
be implicated in both drug metabolism and the systemic inflammatory response from CPB 395 
this would appear to be a more useful indicator of this effect and worth investigating 396 
in the future. 397 
 398 
4.3 Amiodarone 399 
Amiodarone was the only interacting drug which correlated with warfarin sensitivity 400 
in this study, however, it failed to reach significance when included in our model. 401 
One possible reason for this could be the temporal trajectory over which the 402 
interaction occurs. If we were to conduct the study over a longer period for example, 403 
we may find this predictor plays a more prominent role in our model.  404 
 405 
4.4 Limitations 406 
A patient’s response to warfarin therapy can be affected by various factors, including 407 
diet (vitamin K intake), genotype, and co-prescribed interacting drugs.  Whilst we 408 
included major interacting drugs in our model, we did not collect data on genotype, 409 
or diet.  Doing so may have improved our model.  However, with respect to genotype, 410 
this is a factor which is not routinely screened for in the UK, and its inclusion in 411 
this model may have meant that using it as a risk prediction, or dosing tool would 412 
not be practical. 413 
 414 
One further limitation includes the small sample size, and use of a single site for 415 
recruitment.  Despite the small numbers of patients, out study was powered to identify 416 
predictor variables that had a medium, and hence clinically important effect size.  417 
Nevertheless, further research is required to confirm these preliminary findings, and 418 
validate our model in a more diverse patient population. 419 
 420 
 421 
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5. Conclusion 422 
 423 
In this study, we found that 37% of patients had an INR above their therapeutic range 424 
and 29% had an INR ≥4.0, which can lead to patient harm and delay discharge from 425 
hospital.  We identified two clinical markers that contributed to increased 426 
postoperative sensitivity to warfarin in patients that had undergone a range of valve 427 
related and non-valve related cardiac surgery.  These were LVEF and length of cross-428 
clamp time.  By adding these to a linear regression model, they accounted for 41% of 429 
the variance in response to warfarin in the initial loading period in this cohort.  430 
Application of a log WDI cut-off value of -0.380 was able to successfully identify 431 
75% of patients with and INR ≥4.  It should be noted however that this is a single 432 
centre study, and further research is required to confirm these findings in a more 433 
diverse patient population, and rule out the influence of confounders.  But, once 434 
validated, our model could be used to predict patients that are sensitive to warfarin 435 
following cardiothoracic surgery, and provide guidance of a suitable loading dose to 436 
achieve a target INR.  This could reduce the risk of over anticoagulation in the early 437 
postoperative stages and lead to significant improvements in the dosing of this 438 
population. 439 
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Figure 1. Differences between warfarin sensitivity (log WDI) and categories of left 556 
ventricular ejection fraction (LVEF) for patients undergoing cardiothoracic surgery 557 
and participating in the study (n = 41).   The category of LVEF was assigned according 558 
to the British Society of Echocardiography Guidelines [19]: Good = ≥ 55%, mild = 45 559 
- 54%, moderate = 36 - 44% and poor = ≤ 35%.  Outliers are denoted by circular dots, 560 
indicating 1.5 times the box length and extreme outliers are denoted by * indicating 561 
3 times the box length. Kruskal-Wallis test, * p < 0.05. 562 
 563 
Figure 2. Scatter plots demonstrating the relationship between the two variables: 564 
Left Ventricular Ejection Fraction (LVEF, R2=0.32, p<0.001) and Cross Clamp Time 565 
(R2=0.013, p<0.05), and warfarin sensitivity (logWDI).  566 
 567 
Figure 3.  Receiver operating characteristics (ROC) curve showing the sensitivity and 568 
1-specificity values for a range of predicted log WDI cut-off values. The area under 569 
the ROC was found to be 0.70 (p=0.05). 570 
  571 
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Table 1.  Characteristics of participants initiated on warfarin after cardiothoracic 572 
surgery who consented to participate in the study (n = 41).  One patient was an 573 
emergency admission so a pre-operative weight was not documented (in this case the 574 
first weight after surgery was used).  Data are presented as the mean ± standard 575 
deviation unless otherwise stated. 576 
 577 
Characteristic Descriptive Statistic  
Age (years) Median = 65 IQR = 56 - 71 
(range = 28 - 85) 
Gender n (%) Male = 31 (76%) 
Female = 10 (24%) 
Weight (kg) 
(n = 40) 
Mean = 81 ± 19.4 
(Range = 47 - 128) 
 578  579   580 
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Table 2. Indication for warfarin after cardiothoracic surgery for patients 581 
participating in the study (n = 41). 582  583  584 
Indication for Warfarin Therapy n (%) 
Mechanical Mitral Valve 10 (24.4) 
Mechanical Aortic Valve 5 (12.2) 
Tissue Mitral Valve 4 (9.8) 
Mitral Valve Repair 11 (26.8) 
Atrial Fibrillation 10 (24.4) 
Left Ventricular Thrombus 1 (2.4)  585   586 
 26 
Table 3.  Linear regression model of predictors of log WDI with 95% confidence 587 
intervals reported in parentheses.  Confidence intervals and standard errors (SE) 588 
based on 1000 bootstrap samples.  Model 1 contains LVEF and Model 2 contains LVEF and 589 
length of cross-clamp time.  R2=0.33 for model 1 and delta R2=0.085 for Model 2 590 
(p=0.040). SE=Standard error of the mean; CI=95% confidence interval 591 
 592 
Model Coefficients  
((95% CI) 
SE P value 
1. Constant 
    
   LVEF 
0.308 
(- 0.071, 0.428) 
- 0.012 
(- 0.15, - 0.008) 
0.092 
 
0.002 
0.069 
 
0.000352 
2. Constant 
 
   LVEF 
 
   Cross-clamp time 
0.026 
(- 0.468, 0.425) 
- 0.011 
(- 0.015, - 0.004) 
0.002 
(0.0001, 0.005) 
0.217 
 
0.003 
 
0.001 
0.901 
 
0.000352 
 
0.040 
 593 
